Induced Proximity Meets Oncology: A New Era In Cancer Therapy | Dr. Angela Coxon, Ph.D., Vice President of Research and Development, Amgen

Episode notes

Send us Fan Mail For more than 30 years, small cell lung cancer has remained one of the most aggressive and difficult-to-treat cancers - marked by rapid progression, high relapse rates, and very few meaningful advances. But that may finally be starting to change. Today, we’re joined by Dr. Angela Coxon, Ph.D., Vice President of Research and Development at Amgen ( ), where she helps lead the development of next-generation therapies aimed at tackling exactly these kinds of challenges. Her work spans discovery research, translational medicine, and molecular oncology - bridging the gap between early scientific insight and real-world impact for patients. If you’ve been following the show, you may remember our conversation with Amgen's Dr. Ryan Potts, where we explored the emerging concept of Induced Proximity - the idea that instead of simply blocking biology, we can design drugs that bring components together to create entirely new functions.

Related episodes across the Index

Other episodes covering the same guests and topics, from across The B2B Podcast Index.

• Putting the “Tech” in Biotech: An Unconventional Path to Building a Therapeutics Company, with Federico Paoletti, PhDBuilding Biotechs · on Immunotherapy72 / 100
• #139 Justin Coombs, COO at AusHealth on Revolutionising Healthcare Through InnovationCreating Synergy Podcast · on Immunotherapy71 / 100
• This Just In Radio: CancerX 2026 with Dr. John Cleveland and Xavier AvatThis Just In Radio Show · on Immunotherapy68 / 100
• Inside the Physician Decisions That Make Oncology Trials Safer & SmarterLife Science Success · on Immunotherapy54 / 100
• GLP-1s May Reduce Cancer ProgressionCareTalk: Healthcare. Unfiltered. · on Cancer Research36 / 100

• Building the Internet of Medicine: How AI Could Transform Children's Healthcare | Dr. Timothy Chou - Founder, Pediatric Moonshot92 / 100
• Inside the Global Biotech Ecosystem - Where Innovation Goes Next | Sara Jane Demy - Founder and CEO, Demy-Colton
• Reversing Cellular Age: The Scientist Who Helped Create iPS Cells Reveals What’s Next - Dr. Koji Tanabe, Ph.D. - Founder and CEO, I Peace Inc.
• The End of High Cholesterol? The First Oral PCSK9 Drug Could Change Heart Medicine Forever - Dr. Norman Lepor, MD - Founder and Director, National Heart Institute
• The Hidden Heart Risk: Amgen’s Dr. Paul Burton on the Future of Preventing Heart Attacks - Dr. Paul Burton, M.D., Ph.D., F.A.C.C., M.R.C.S., F.R.C.P. - Senior Vice President and Chief Medical Officer - Amgen